The fight against cancer needs new, big, bold ideas. At Siren, we’ve got one: Universal AAV Immuno-Gene Therapy. We are combining two transformative therapeutic technologies – AAV gene therapy and cytokine immunotherapy - into a single, reimagined modality that overcomes key challenges and redefines how we destroy tumor cells and elicit anti-tumor immunity.
Location: United States, California, San Francisco
Employees: 1-10
Investors 3
| Date | Name | Website |
| 06.08.2024 | NZVC | nzvc.co.nz |
| - | Carnrite V... | carnriteve... |
| - | Hawktail M... | hawktail.c... |
Mentions in press and media 3
| Date | Title | Description |
| 16.01.2024 | WhiteLab Genomics and Siren Biotechnology Announce Partnership to Accelerate AI-Powered Advancements in Gene Therapy | PARIS, FRANCE, January 16, 2024 /EINPresswire.com/ -- WhiteLab Genomics, artificial intelligence (AI) leaders in genomic medicine, and Siren Biotechnology, the innovators of universal AAV immuno-gene therapy for cancer, today announced a st... |
| 01.11.2023 | Siren Biotechnology Awarded $4M in Grant Funding from the California Institute for Regenerative Medicine (CIRM) | - |
| - | Siren Biotechnology | “Siren Biotechnology” |